NOVEL THERAPIES & NEXT-GEN MEDICAL DEVICES IN CARDIOVASCULAR & VASCULAR DISEASE MANAGEMENT
With
Professor Shirley Jansen AM
The Lawrence-Brown Chair of Vascular Surgery,
School of Population Health,
Curtin University &
Head of the Department of Vascular and Endovascular Surgery,
Sir Charles Gairdner Hospital &
Director of the Heart and Vascular Research Institute,
Harry Perkins Institute of Medical Research, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | June 2026
Professor Shirley Jansen AM is a distinguished vascular and endovascular surgeon whose career spans clinical leadership, academic excellence, and pioneering research. She currently holds the Lawrence-Brown Chair of Vascular Surgery at Curtin University’s School of Population Health and serves as Head of the Department of Vascular Surgery at Sir Charles Gairdner Hospital, a role she has held since 2015. In addition, she is the Director of the Heart & Vascular Research Institute at the Harry Perkins Institute for Medical Research. Her early career was marked by prestigious fellowships, including a British Heart Foundation Research Fellowship (1996), and multiple international travelling fellowships from leading surgical societies and industry sponsors between 2001 and 2002.
Professor Jansen has over 20 years of experience treating vascular disease and has played a vital role in shaping healthcare policy, and clinical standards. She has been Site PI in over 50 clinical trials in pharma, device, first in man, RCTS and registries, many global and leading to changes in practice. She has over 150 peer-reviewed publications, including chapters in key surgical textbooks. Her research has attracted over $14 million in funding, supporting groundbreaking work in biologic therapeutics, vascular medicine, and international clinical trials.
Professor Jansen is Co-Founder and Director of Atherid Therapeutics Pty Ltd developing a novel first in class therapeutic to remove cholesterol and lipid from the arterial wall in atherosclerosis with inventor A/Prof Juliana Hamzah, Head of Targeted Drug Delivery, Imaging and Therapeutics Lab, Harry Perkins Institute of Medical Research. S Jansen’s other main research interest is in the mechanical impacts on the vessel wall as it relates to arterial disease and intervention, and the development of 3D bioprinted vascular devices with her colleague A/Prof Elena Juan Pardo, an expert in bioengineering at the Perkins.
Source: Supplied
-
Exercise program for the prevention of osteoporotic fracture
Dr Beck is an international leader in the effects of mechanical loading on bone health. Dr Beck graduated from The University of Queensland (BHMS[Ed]) and the University of Oregon (MSc and PhD) and completed a postdoctoral research fellowship in the Stanford University School of Medicine (California, USA.) She is a Professor of Exercise Science at Griffith University Gold Coast campus, where she has led the Bone Densitometry Research Laboratory since 2004.
-
Antimicrobial technologies & drug delivery platforms
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
